The critical role of the bone marrow stromal microenvironment for the development of drug screening platforms in leukemia

High-throughput screening has revolutionized drug development and monumentally decreased the costs associated with testing compound libraries [1]. Despite such advances, there has been little change in the success rate of commercial drug development for novel therapies [1,2]. Although the use of tumor cell monocultures in high-throughput drug screening has been used as the conventional platform for identifying new treatments for leukemia [3], novel cancer therapeutics displaying seemingly promising in vitro efficacy from such drug screening platforms often fail to translate their expected advantages [4,5].
Source: Experimental Hematology - Category: Hematology Authors: Tags: Review Article Source Type: research